Class information for: |
Basic class information |
Class id | #P | Avg. number of references |
Database coverage of references |
---|---|---|---|
1422 | 7962 | 35.8 | 81% |
Hierarchy of classes |
The table includes all classes above and classes immediately below the current class. |
Cluster id | Level | Cluster label | #P |
---|---|---|---|
6 | 4 | GASTROENTEROLOGY & HEPATOLOGY//ONCOLOGY//SURGERY | 1371034 |
216 | 3 | NON SMALL CELL LUNG CANCER//LUNG CANCER//THORAC SURG | 51214 |
1422 | 2 | XRCC1//GEMCITABINE//ERCC1 | 7962 |
683 | 1 | NON SMALL CELL LUNG CANCER//VINORELBINE//GEMCITABINE | 3165 |
2272 | 1 | XRCC1//XRCC3//XPD | 2300 |
8385 | 1 | GEMCITABINE//DEOXYCYTIDINE KINASE//HENT1 | 1259 |
13007 | 1 | ERCC1//RRM1//MED OVARIAN CANC SECT | 866 |
22701 | 1 | PEMETREXED//MULTITARGETED ANTIFOLATE//AFFILIATED JIANGSU CANC HOSP | 372 |
Terms with highest relevance score |
rank | Term | termType | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|---|
1 | XRCC1 | authKW | 1061812 | 5% | 77% | 362 |
2 | GEMCITABINE | authKW | 946290 | 12% | 25% | 986 |
3 | ERCC1 | authKW | 842115 | 4% | 70% | 312 |
4 | NON SMALL CELL LUNG CANCER | authKW | 677194 | 16% | 14% | 1308 |
5 | PEMETREXED | authKW | 522425 | 4% | 42% | 327 |
6 | XRCC3 | authKW | 425369 | 2% | 84% | 132 |
7 | XPD | authKW | 290651 | 2% | 59% | 128 |
8 | VINORELBINE | authKW | 228695 | 3% | 25% | 237 |
9 | ERCC2 | authKW | 207355 | 1% | 78% | 69 |
10 | LUNG CANCER | journal | 201871 | 6% | 11% | 483 |
Web of Science journal categories |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | Oncology | 142838 | 68% | 1% | 5435 |
2 | Respiratory System | 12608 | 11% | 0% | 862 |
3 | Pharmacology & Pharmacy | 1658 | 11% | 0% | 869 |
4 | Genetics & Heredity | 1270 | 7% | 0% | 530 |
5 | Toxicology | 440 | 3% | 0% | 241 |
6 | Medicine, Research & Experimental | 211 | 3% | 0% | 252 |
7 | Hematology | 100 | 2% | 0% | 155 |
8 | Pathology | 66 | 2% | 0% | 124 |
9 | Biotechnology & Applied Microbiology | 60 | 3% | 0% | 221 |
10 | Public, Environmental & Occupational Health | 31 | 2% | 0% | 185 |
Address terms |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | MED ONCOL | 72398 | 12% | 2% | 942 |
2 | AFFILIATED JIANGSU CANC HOSP | 53999 | 0% | 41% | 34 |
3 | MED OVARIAN CANC SECT | 45387 | 0% | 79% | 15 |
4 | TERRY FOX CANC | 45040 | 1% | 29% | 40 |
5 | THORAC ONCOL | 44582 | 2% | 8% | 156 |
6 | CATHEDRAL MOTHERS CHILDS HLTH | 34845 | 0% | 91% | 10 |
7 | THORAC ONCOL UNIT | 26835 | 0% | 22% | 32 |
8 | THORAC ONCOL PROGRAM | 26680 | 0% | 18% | 39 |
9 | CHEMOTHER Y | 25515 | 1% | 7% | 90 |
10 | CLIN GYNAECOL SURG | 23477 | 0% | 88% | 7 |
Journals |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | LUNG CANCER | 201871 | 6% | 11% | 483 |
2 | SEMINARS IN ONCOLOGY | 74164 | 4% | 6% | 318 |
3 | JOURNAL OF THORACIC ONCOLOGY | 43141 | 2% | 7% | 174 |
4 | CLINICAL LUNG CANCER | 38954 | 1% | 12% | 88 |
5 | ASIAN PACIFIC JOURNAL OF CANCER PREVENTION | 28450 | 3% | 4% | 205 |
6 | CANCER CHEMOTHERAPY AND PHARMACOLOGY | 25212 | 3% | 3% | 221 |
7 | ANNALS OF ONCOLOGY | 24140 | 3% | 3% | 229 |
8 | TUMOR BIOLOGY | 13808 | 2% | 2% | 150 |
9 | JOURNAL OF CLINICAL ONCOLOGY | 13744 | 3% | 2% | 244 |
10 | CANCER TREATMENT REPORTS | 10182 | 1% | 4% | 77 |
Author Key Words |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | XRCC1 | 1061812 | 5% | 77% | 362 | Search XRCC1 | Search XRCC1 |
2 | GEMCITABINE | 946290 | 12% | 25% | 986 | Search GEMCITABINE | Search GEMCITABINE |
3 | ERCC1 | 842115 | 4% | 70% | 312 | Search ERCC1 | Search ERCC1 |
4 | NON SMALL CELL LUNG CANCER | 677194 | 16% | 14% | 1308 | Search NON+SMALL+CELL+LUNG+CANCER | Search NON+SMALL+CELL+LUNG+CANCER |
5 | PEMETREXED | 522425 | 4% | 42% | 327 | Search PEMETREXED | Search PEMETREXED |
6 | XRCC3 | 425369 | 2% | 84% | 132 | Search XRCC3 | Search XRCC3 |
7 | XPD | 290651 | 2% | 59% | 128 | Search XPD | Search XPD |
8 | VINORELBINE | 228695 | 3% | 25% | 237 | Search VINORELBINE | Search VINORELBINE |
9 | ERCC2 | 207355 | 1% | 78% | 69 | Search ERCC2 | Search ERCC2 |
10 | DNA REPAIR GENES | 182147 | 1% | 49% | 98 | Search DNA+REPAIR+GENES | Search DNA+REPAIR+GENES |
Core articles |
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c: (1) Number of references referring to publications in the class. (2) Share of total number of active references referring to publications in the class. (3) Age of the article. New articles get higher score than old articles. (4) Citation rate, normalized to year. |
Rank | Reference | # ref. in cl. |
Shr. of ref. in cl. |
Citations |
---|---|---|---|---|
1 | FENG, YZ , LIU, YL , HE, XF , WEI, W , SHEN, XL , XIE, DL , (2014) ASSOCIATION BETWEEN THE XRCC1 ARG194TRP POLYMORPHISM AND RISK OF CANCER: EVIDENCE FROM 201 CASE-CONTROL STUDIES.TUMOR BIOLOGY. VOL. 35. ISSUE 11. P. 10677 -10697 | 183 | 92% | 6 |
2 | STEWART, DJ , CHIRITESCU, G , DAHROUGE, S , BANERJEE, S , TOMIAK, EM , (2007) CHEMOTHERAPY DOSE - RESPONSE RELATIONSHIPS IN NON-SMALL CELL LUNG CANCER AND IMPLIED RESISTANCE MECHANISMS.CANCER TREATMENT REVIEWS. VOL. 33. ISSUE 2. P. 101-137 | 222 | 81% | 12 |
3 | HE, XF , WEI, W , LI, JL , SHEN, XL , DING, DP , WANG, SL , LIU, ZZ , QIN, JB , WU, LX , XIE, DL , (2013) ASSOCIATION BETWEEN THE XRCC3 T241M POLYMORPHISM AND RISK OF CANCER: EVIDENCE FROM 157 CASE-CONTROL STUDIES.GENE. VOL. 523. ISSUE 1. P. 10 -19 | 133 | 90% | 17 |
4 | ELNAGGAR, M , GIOVANNETTI, E , PETERS, GJ , (2012) MOLECULAR TARGETS OF GEMCITABINE ACTION: RATIONALE FOR DEVELOPMENT OF NOVEL DRUGS AND DRUG COMBINATIONS.CURRENT PHARMACEUTICAL DESIGN. VOL. 18. ISSUE 19. P. 2811-2829 | 159 | 73% | 13 |
5 | SCULIER, JP , MORO-SIBILOT, D , (2009) FIRST- AND SECOND-LINE THERAPY FOR ADVANCED NONSMALL CELL LUNG CANCER.EUROPEAN RESPIRATORY JOURNAL. VOL. 33. ISSUE 4. P. 915-930 | 129 | 91% | 29 |
6 | MACERELLI, M , GANZINELLI, M , GOUEDARD, C , BROGGINI, M , GARASSINO, MC , LINARDOU, H , DAMIA, G , WIESMULLER, L , (2016) CAN THE RESPONSE TO A PLATINUM-BASED THERAPY BE PREDICTED BY THE DNA REPAIR STATUS IN NON-SMALL CELL LUNG CANCER?.CANCER TREATMENT REVIEWS. VOL. 48. ISSUE . P. 8 -19 | 105 | 67% | 2 |
7 | KOBERLE, B , KOCH, B , FISCHER, BM , HARTWIG, A , (2016) SINGLE NUCLEOTIDE POLYMORPHISMS IN DNA REPAIR GENES AND PUTATIVE CANCER RISK.ARCHIVES OF TOXICOLOGY. VOL. 90. ISSUE 10. P. 2369 -2388 | 127 | 61% | 0 |
8 | ZHOU, PT , LI, B , JI, J , WANG, MM , GAO, CF , (2015) A SYSTEMATIC REVIEW AND META-ANALYSIS OF THE ASSOCIATION BETWEEN OGG1 SER326CYS POLYMORPHISM AND CANCERS.MEDICAL ONCOLOGY. VOL. 32. ISSUE 2. P. - | 94 | 82% | 0 |
9 | CICCOLINI, J , SERDJEBI, C , PETERS, GJ , GIOVANNETTI, E , (2016) PHARMACOKINETICS AND PHARMACOGENETICS OF GEMCITABINE AS A MAINSTAY IN ADULT AND PEDIATRIC ONCOLOGY: AN EORTC-PAMM PERSPECTIVE.CANCER CHEMOTHERAPY AND PHARMACOLOGY. VOL. 78. ISSUE 1. P. 1 -12 | 81 | 80% | 2 |
10 | WEI, BB , ZHOU, Y , XU, ZQ , XI, B , CHENG, H , RUAN, J , ZHU, M , HU, Q , WANG, Q , WANG, ZR , ET AL (2011) THE EFFECT OF HOGG1 SER326CYS POLYMORPHISM ON CANCER RISK: EVIDENCE FROM A META-ANALYSIS.PLOS ONE. VOL. 6. ISSUE 11. P. - | 89 | 86% | 16 |
Classes with closest relation at Level 2 |